Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy
Ulrich Keilholz(German Cancer Research Center), Michael B. Atkins(Georgetown University), Mary L. Disis(University of Washington), Dmitry I. Gabrilovich(AstraZeneca (Netherlands)), Jeffrey S. Weber(NYU Langone Health), W. Martin Kast(University of Southern California), James H. Finke(Palm Beach Atlantic University), Walter J. Storkus(University of Pittsburgh Medical Center), Peter P. Lee(City Of Hope National Medical Center), Carmen Scheibenbogen(University of Freiburg), Franceso Marincola(Universal-Kugellager-Fabrik (Germany)), Jeff Schlom(Universal-Kugellager-Fabrik (Germany)), Alexandra S. Worobec(Loyola University Medical Center), John M. Kirkwood(UPMC Hillman Cancer Center), Vernon C. Maino(BD Biosciences (United States)), H. Kim Lyerly(Duke University)
Cited by 299
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k